Target RWE

🚀 #TargetRWE is excited to announce a major milestone in our strategic partnership with the American Association for the Study of Liver Diseases (AASLD) — the enrollment of over 600,000 patients in the #TARGETLIVERDISEASE (TARGET-LD) observational study! This groundbreaking effort supports the #CirrhosisQualityCollaborative (CQC) and aims to bridge the gap between best practices and current care to improve outcomes for patients living with #cirrhosis and other #chronicliverdiseases. 👏 We're proud to continue collaborating with #AASLD to drive meaningful change in the fight against #liverdisease. Learn more today: https://lnkd.in/gZVkzxqC #RealWorldEvidence #TARGETLD #LiverHealth #MedicalResearch #HealthInnovation #TargetRWE #LiverResearch #CQC

Special congratulations to our TARGET-IBD co-chair, Millie D. Long, MD, MPH, for being recognized with this year's prestigious Sherman Prize! 🏆👏 Your exceptional contributions to the field of #InflammatoryBowelDisease inspire us and we're thankful for your continued support. Learn more 👉 https://lnkd.in/emVFFn27 #RealWorldEvidence #ShermanPrize #TargetRWE

What a year for #TargetRWE! 👏🎉 In 2024, we expanded our real-world longitudinal studies, partnered with leading organizations, and presented research at top academic & medical conferences - including #LiverDisease research on #GLP1 receptor agonists and novel #Epidemiology methods designed to safeguard data integrity. Learn more 👉 https://lnkd.in/euikhM54 #RealWorldEvidence #RealWorldData #DataAnalytics #ClinicalResearch #HealthcareData #HealthcareResearch #RWE #Gastroenterology #Dermatology #NovelData #YearInReview

This year, #TargetRWE broke new ground in #RealWorldEvidence! From publishing 5 manuscripts and presenting 34 posters to advancing our growing longitudinal studies like TARGET-LD and TARGET-GASTRO, we’ve expanded the boundaries of #RWE. Our real-world studies on #GLP1 RAs, #EosinophilicEsophagitis, #AtopicDermatitis, and novel methods in #Epidemiology are driving actionable insights and transforming patient care. Click the link below to read our 2024 year in review 👇🌟 #Innovation #RWE #ClinicalResearch #LiverDisease #IBD #Gastroenterology #Dermatology #SkinDisease #RealWorldData #ClinicalResearch #DataAnalytics

🎬 📊 New Research from #TargetRWE at #TheLiverMeeting2024! Co-chair of the TARGET-NASH steering committee, Arun J. Sanyal, MBBS, MD, presents groundbreaking findings from the study: “Stability of the NASH-CHECK Patient-Reported Outcome Measure Over Time in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Stable Clinical Status.” Using data from #TARGETNASH, this study delves into the reliability & consistency of the NASH-CHECK measure in #MASLD patients, even when conditions remains stable. Watch the video & click the link to learn more about our activity at #TLM2024: https://lnkd.in/eKZ9ERUP #NASH #MASH #PatientReportedOutcomes #LiverResearch #LiverHealth #LiverDisease #RealWorldEvidence #RealWorldData #NASHCHECK #PatientData #FattyLiver

📊 New research from #TargetRWE sheds light on the NASH-CHECK PROM for #MASLD patients! Our studies at #TheLiverMeeting2024 show NASH-CHECK scores remain stable over time, supporting its use in drug development and #PatientManagement. Additionally, we found worse scores in patients with #DecompensatedCirrhosis, highlighting the impact of disease progression. Click the link to read more: https://lnkd.in/gUf3_XEi #NASH ##LiverDisease #PatientReportedOutcomes #RealWorldEvidence #LiverResearch 

🧬🎤 To follow up yesterdays research presentation by #TARGETNASH steering committee member, A. Sidney Barritt IV, MD, MSCR, #TargetRWE is proud to highlight Dr. Barritt's interview with HCPLive where he further expands on the potential impact of Glucagon-Like Peptide 1 Receptor Agonists (GLP-1RAs) usage in patients with Metabolic-Dysfunction Associated Steatotic Liver Disease (MASLD). Click the link to hear from Dr. Barritt about the potential impact of #GLP1RA use and it's association with a reduced risk of mortality and disease progression in #MASLD patients: https://lnkd.in/gQCgeJ_a #GLP1 #TheLiverMeeting #LiverResearch #LiverHealth #RealWorldData #RealWorldEvidence #ClinicalResearch

🎬 New Research from #TargetRWE at #TheLiverMeeting2024! A. Sidney Barritt IV, MD, MSCR, member of the TARGET-NASH steering committee, presented new findings on the impact of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). This real-world study shows that #GLP1RAs are associated with slower disease progression and lower all-cause mortality in #MASLD patients. Watch Dr. Barritt's insightful presentation to learn more about how these treatments could transform outcomes for MASLD patients: https://lnkd.in/geiX3vk3 #MASLD #GLP1RA #LiverDisease #RealWorldEvidence #LiverHealth #TargetRWE #TLM2024 #NASH #LiverResearch

▶️📈 Exciting Research from #TargetRWE at #ACG2024! A. Sidney Barritt IV, MD, MSCR, lead author and member of the #TARGETNASH steering committee, presented groundbreaking findings at the American College of Gastroenterology 2024 on the real-world impact of specific medications in patients with #MASLD. In this presentation, Dr. Barritt shares insights from the TARGET-NASH cohort, exploring the association between medication use and key #PatientOutcomes, including #Mortality and #DiseaseProgression. 🔍 Watch now to learn about the latest findings and their potential to change patient care: https://lnkd.in/gwUtRPVN  #ClinicaResearch #LiverDisease #HealthcareInnovation #LiverResearch #RealWorldEvidence #RealWorldData 

🎥 📈 Uncovering Barriers to Eosinophilic Esophagitis Treatment. Check out this insightful presentation by TARGET-EGIDs Steering Committee Chair, Evan S. Dellon, MD, MPH, where he discusses a new #TargetRWE study on #EoE treatment patterns. Watch the video to learn about the factors associated with patients who don't receive medication, even after diagnosis. Click the link to learn more about our activity at #ACG2024: https://lnkd.in/gWSm_rAM #Gastroenterology #RealWorldEvidence #ClinicalResearch #PatientJourneys #PatientCare